{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:56Z","timestamp":1786991096108,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2022.109623","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:28:45Z","timestamp":1671589725000},"page":"109623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial"],"prefix":"10.1016","volume":"115","author":[{"given":"Mohsen","family":"Gholinataj jelodar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Rafieian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Saghafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Hadad zedegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Birjandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Rafieian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Allah dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Dehghanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Khalaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Dehghan Chenari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Hajimaghsoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed","family":"Mojtaba Sohrevardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.intimp.2022.109623_b0005","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"New England Journal of Medicine."},{"issue":"4","key":"10.1016\/j.intimp.2022.109623_b0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"The Lancet respiratory medicine."},{"key":"10.1016\/j.intimp.2022.109623_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: A review","volume":"215","author":"Yuki","year":"2020","journal-title":"Clinical immunology."},{"key":"10.1016\/j.intimp.2022.109623_b0020","series-title":"Clinical management of COVID-19: interim guidance, 27 May 2020","author":"Organization","year":"2020"},{"issue":"10223","key":"10.1016\/j.intimp.2022.109623_b0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"The lancet."},{"issue":"10223","key":"10.1016\/j.intimp.2022.109623_b0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. The lancet."},{"issue":"7","key":"10.1016\/j.intimp.2022.109623_b0035","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"Journal of medical virology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109623_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"10.1016\/j.intimp.2022.109623_b0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nature reviews immunology."},{"key":"10.1016\/j.intimp.2022.109623_b0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5935\/0103-507X.20200060","article-title":"Rationale and design of the \u201cTocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled\u201d trial (TOCIBRAS)","volume":"32","author":"Farias","year":"2020","journal-title":"Revista Brasileira de terapia intensiva."},{"issue":"2","key":"10.1016\/j.intimp.2022.109623_b0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"New England Journal of Medicine."},{"issue":"10241","key":"10.1016\/j.intimp.2022.109623_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31282-4","article-title":"Early evidence of pronounced brain involvement in fatal COVID-19 outcomes","volume":"395","author":"von Weyhern","year":"2020","journal-title":"The Lancet."},{"issue":"12","key":"10.1016\/j.intimp.2022.109623_b0065","doi-asserted-by":"crossref","first-page":"166559","DOI":"10.1016\/j.bbadis.2022.166559","article-title":"Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health","volume":"1868","author":"Lo Presti","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.109623_b0070","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5114\/aoms\/130647","article-title":"It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?","volume":"17","author":"Ghanei","year":"2021","journal-title":"Arch Med Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109623_b0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA internal medicine."},{"issue":"6","key":"10.1016\/j.intimp.2022.109623_b0080","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/ejhpharm-2020-002669","article-title":"Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19","volume":"29","author":"Moreno Diaz","year":"2022","journal-title":"Eur J Hosp Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2022.109623_b0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA internal medicine."},{"issue":"s1","key":"10.1016\/j.intimp.2022.109623_b0090","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1046\/j.1440-1843.2003.00525.x","article-title":"Zhong NS. SARS: pharmacotherapy","volume":"8","author":"Tsang","year":"2003","journal-title":"Respirology."},{"issue":"2","key":"10.1016\/j.intimp.2022.109623_b0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000487224","article-title":"Lectin affinity plasmapheresis for middle east respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination","volume":"46","author":"Koch","year":"2018","journal-title":"Blood purification."},{"issue":"1","key":"10.1016\/j.intimp.2022.109623_b0100","article-title":"The place of plasmapheresis in septic patients complicated with disseminated intravascular coagulation","volume":"8","author":"Oral","year":"2004","journal-title":"Critical care."},{"issue":"9","key":"10.1016\/j.intimp.2022.109623_b0105","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s42399-020-00438-2","article-title":"Efficacy of plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients with COVID-19","volume":"2","author":"Pourahmad","year":"2020","journal-title":"SN Comprehensive Clinical Medicine."},{"issue":"11","key":"10.1016\/j.intimp.2022.109623_b0110","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.4103\/jfmpc.jfmpc_578_21","article-title":"Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center","volume":"10","author":"Mohanty","year":"2021","journal-title":"Journal of Family Medicine and Primary Care."},{"key":"10.1016\/j.intimp.2022.109623_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","article-title":"Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u03b2 in non-ST-elevation myocardial infarction","volume":"271","author":"Kleveland","year":"2018","journal-title":"International Journal of Cardiology."},{"issue":"2","key":"10.1016\/j.intimp.2022.109623_b0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2991\/jegh.k.201222.001","article-title":"The role of convalescent plasma and tocilizumab in the management of COVID-19 infection: A cohort of 110 patients from a tertiary care hospital in Oman","volume":"11","author":"Khamis","year":"2021","journal-title":"Journal of Epidemiology and Global Health."},{"issue":"10","key":"10.1016\/j.intimp.2022.109623_b0125","first-page":"3959","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease, Blood","volume":"112","author":"Nishimoto","year":"2008","journal-title":"The Journal of the American Society of Hematology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109623_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05701-4","article-title":"Effects of Tocilizumab in COVID-19 patients: a cohort study","volume":"20","author":"Vu","year":"2020","journal-title":"BMC infectious diseases."},{"issue":"3","key":"10.1016\/j.intimp.2022.109623_b0135","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/jmv.26698","article-title":"Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection","volume":"93","author":"Ivan Hariyanto","year":"2021","journal-title":"Journal of Medical Virology."},{"issue":"4","key":"10.1016\/j.intimp.2022.109623_b0140","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.chest.2020.06.006","article-title":"Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes","volume":"158","author":"Price","year":"2020","journal-title":"Chest."},{"issue":"4","key":"10.1016\/j.intimp.2022.109623_b0145","first-page":"742","article-title":"Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration","volume":"38","author":"Conrozier","year":"2020","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.intimp.2022.109623_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators of inflammation."},{"issue":"8","key":"10.1016\/j.intimp.2022.109623_b0155","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"The Lancet Rheumatology."},{"issue":"4","key":"10.1016\/j.intimp.2022.109623_b0160","doi-asserted-by":"crossref","first-page":"103433","DOI":"10.1016\/j.transci.2022.103433","article-title":"Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome","volume":"61","author":"Beraud","year":"2022","journal-title":"Transfusion and Apheresis Science."},{"issue":"6","key":"10.1016\/j.intimp.2022.109623_b0165","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.pulmoe.2020.10.017","article-title":"Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)","volume":"27","author":"Hashemian","year":"2021","journal-title":"Pulmonology."},{"key":"10.1016\/j.intimp.2022.109623_b0170","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijid.2020.06.064","article-title":"Therapeutic plasma exchange in adults with severe COVID-19 infection","volume":"99","author":"Khamis","year":"2020","journal-title":"International Journal of Infectious Diseases."},{"issue":"1","key":"10.1016\/j.intimp.2022.109623_b0175","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anaesthesiology intensive therapy."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:03:57Z","timestamp":1736413437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922011080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"alternative-id":["S1567576922011080"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109623","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109623"}}